Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

6 Nov 2019

Abstract excerpt

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Pancreatic and Hepatic Oncology Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31690319
DOI: 10.1186/s12943-019-1091-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4PMID 31690319Read ↗

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity Read ↗

Immune Checkpoint Inhibitors to Treat Malignant LymphomasSemantic proximity Read ↗

Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.Semantic proximity Read ↗

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read ↗

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitorsSemantic proximity Read ↗

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsSemantic proximity Read ↗

Immune checkpoints and cancer in the immunogenomics eraSemantic proximity Read ↗

Viewing the immune checkpoint VISTA: landscape and outcomes across cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.